MusclePharm Reports 2013 Fourth Quarter and Full Year Financial
Results
2013 Fourth Quarter Revenue Increases 127% to $37.5 Million;
Full Year Revenue Grew 65% to $110.9 Million
Reaffirms Guidance of Approximately $150 Million in Annual Sales
With Earnings per Diluted Share of $0.20 to $0.22 to Achieve First
Year of Profitability
Conference Call Set for 11:00 a.m. Eastern Today
DENVER, CO--(Marketwired - Mar 31, 2014) - MusclePharm
Corporation (OTCQB: MSLP), a leading international, award-winning
sports nutrition company, today announced financial results for the
fourth quarter and full year ended Dec. 31, 2013.
"MusclePharm is becoming a leading lifestyle brand in the sports
nutrition market and our financial performance in 2013 is testament
to the company's ability to drive strong topline growth and connect
with a growing consumer base," said Brad Pyatt, MusclePharm's
chairman and chief executive officer. "We will continue to fuel
MusclePharm's momentum by focusing on executing our growth
initiatives and carrying on the company's commitment to deliver
superior science-based products, while striving to enhance
profitability."
2013 Fourth-Quarter Results
The following comparison refers to results for the fourth
quarter of 2013 versus the fourth quarter of 2012.
Net sales increased 127 percent to $37.5 million from $16.5
million last year. Net sales by distribution channel were as
follows:
- Specialty Market, comprised of brick-and-mortar sales and
e-commerce, increased 65.8 percent to $18.0 million from $10.9
million last year;
- International sales increased 102 percent to $11.3 million from
$5.6 million last year; and,
- FDM (Food, Drug, Mass), a new sales channel, was $8.1 million
versus nil last year.
Gross profit was $9.7 million, compared with $4.1 million last
year. As a percentage of net sales, gross profit was 26
percent, compared with 25 percent last year. Gross margin in
the fourth quarter was impacted by the timing of rebate accruals.
Excluding this impact, gross margins would have been approximately
30 percent.
Operating expenses as a percentage of net sales were 41.8
percent, compared with 40.3 percent last year.
Net loss for the 2013 fourth quarter was approximately $4.0
million, or $0.45 per share, compared with a net loss of
approximately $3.0 million, or $1.12 per share, for the same period
last year.
"Our strong fourth quarter results reflect the launch of new
products and product extensions throughout the year and the
traction they gained throughout our expanding distribution
footprint," Pyatt said. "We believe that MusclePharm's brand
awareness is rapidly increasing across multiple platforms that
engage a diverse and growing audience."
Recent Highlights
- Signed exclusive agreement with USA Wrestling to be its
exclusive official nutritional supplement provider;
- Completed acquisition of substantially all of the assets of
BioZone Pharmaceuticals and its subsidiaries, including assets
associated with BioZone's QuSomes®, HyperSorb™ and EquaSome™
technologies, in addition to BioZone's Baker-Cummins line of
products, and the name "BioZone";
- Announced Amino 1 recovery and hydration sports drink will be
available at 150 Costco locations nationwide mid-January 2014;
- Renewed multi-year agreement with Ultimate Fighting
Championship®; and,
- Repurchased 120,000 shares of common stock for an aggregate
purchase price of approximately $934,000 as part of a $5.0 million
stock repurchase plan approved by the Company's Board of Directors
on December 10, 2013.
2013 Full-Year Results
The following comparison refers to results for the full year of
2013 versus the full year of 2012.
Net sales increased 65 percent to $110.9 million from $67.1
million last year. By segment, net sales were as follows:
- Specialty Market, comprised of brick-and-mortar sales and
e-commerce, increased 46 percent to $68.6 million, from $46.9
million last year;
- International sales increased 69 percent to $34.1 million, from
$20.2 million last year; and,
- FDM (Food, Drug, Mass), a new sales channel, was $8.2 million
versus nil last year.
Gross profit was $33.2 million or 30 percent of net sales,
compared with $14.3 million or 21 percent of net sales. The
year-over-year increase was due to improved supply chain
optimization, operational infrastructure improvements, ERP and
reporting systems integration, and key management hires.
Operating expenses were $47.5 million or 42.8 percent of net
sales, compared with $23.1 million or 34.4 percent of
revenue. The year-over-year increase was related to
infrastructure improvements, new growth platforms and initiatives,
company re-capitalization and staffing increases to establish a
scalable organization.
Net loss was reduced to $17.7 million, or $2.46 per share, from
a net loss of $19.0 million, or $13.00 per share, for the same
period last year. Weighted average number of common shares
outstanding for the period was 7.2 million, compared with 1.5
million last year.
At December 31, 2013, the company had approximately $5.4 million
in cash and $2.5 million in restricted cash.
2014 Full Year Guidance
MusclePharm reiterates its 2014 full-year guidance calling for
revenue of approximately $150 million, with gross margin in the
range of 33 percent.
Diluted earnings per share are expected to be in the range of
$0.20 - $0.22, based on a fully-diluted share count of
approximately 13.5 million.
Guidance does not include the potential impact of share
repurchases under the previously mentioned share repurchase
plan.
"As MusclePharm's momentum continues to build, we remain
committed to improving operating efficiencies and increasing
profitability to ultimately enhance shareholder value," Pyatt said.
"We are very excited about our prospects in 2014 and the
opportunity to deliver exceptional products and heighten
MusclePharm's brand awareness around the world."
2013 Fourth Quarter
Conference Call Information
When: Monday, March 31 Time: 11:00 a.m. Eastern
Phone: 1-877-407-9126 (domestic) 1-201-493-6751
(international)
A live Webcast will be available online on MusclePharm's website
at http://ir.musclepharmcorp.com, where it will be archived for one
year.
About MusclePharm MusclePharm® is a leading international,
award-winning sports nutrition company offering vitamins and
nutritional supplements which are available in more than 110
countries and available in 35,000+ retail outlets, including
Bodybuilding.com, Costco, Dick's Sporting Goods, 24 Hour Fitness,
Walgreens, Bally's, GNC, Vitamin Shoppe and Vitamin World. The
company's brands are MusclePharm®, Arnold Schwarzenegger™ Series,
and FitMiss®. The comprehensive lines of clinically-proven, safe
and effective nutritional supplements are developed through a
six-stage research process that utilizes the expertise of leading
nutritional scientists, doctors and universities. For more
information, visit www.musclepharmcorp.com. Follow the company at
http://www.facebook.com/MusclePharm and
www.Twitter.com/MusclePharm
Forward-Looking Statements This release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities and Exchange
Act of 1934, as amended. Statements that are not a description of
historical facts constitute forward-looking statements and may
often, but not always, be identified by the use of such words as
"expects", "anticipates", "intends", "estimates", "plans",
"potential", "possible", "probable", "believes", "seeks", "may",
"will", "should", "could" or the negative of such terms or other
similar expressions. Actual results may differ materially from
those set forth in this release due to the risks and uncertainties
inherent in the Company's business. More detailed information about
the Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2012,
the Company's Quarter Reports on Form 10-Q and other filings
submitted by the Company to the SEC, copies of which may be
obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and the Company undertakes no obligation to
revise or update this release to reflect events or circumstances
after the date hereof
|
|
|
|
MusclePharm Corporation |
|
Condensed Financial Statements |
|
|
|
|
For the Three Months Ended |
|
|
For the Years Ended |
|
|
December 31, |
|
|
December 31, |
|
|
(unaudited) |
|
|
(audited) |
|
|
2013 |
|
|
2012 |
|
|
2013 |
|
|
2012 |
|
Net
sales |
$ |
37,492,397 |
|
|
$ |
16,491,469 |
|
|
$ |
110,877,591 |
|
|
$ |
67,055,215 |
|
Cost
of goods sold |
|
27,784,504 |
|
|
|
12,381,406 |
|
|
|
77,685,396 |
|
|
|
52,726,934 |
|
Gross
profit |
|
9,707,893 |
|
|
|
4,110,063 |
|
|
|
33,192,195 |
|
|
|
14,328,281 |
|
Operating expenses |
|
15,669,164 |
|
|
|
6,643,427 |
|
|
|
47,488,657 |
|
|
|
23,064,092 |
|
Loss
from operations |
$ |
(5,961,271 |
) |
|
$ |
(2,533,364 |
) |
|
$ |
(14,296,462 |
) |
|
$ |
(8,735,811 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share |
$ |
(0.45 |
) |
|
$ |
(1.12 |
) |
|
$ |
(2.46 |
) |
|
$ |
(13.00 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2013 |
|
December 31, 2012 |
|
|
|
(audited) |
|
(audited) |
|
Assets |
|
|
|
|
|
|
|
Current assets |
|
|
44,526,480 |
|
|
4,949,881 |
|
Property and equipment - net |
|
|
2,613,584 |
|
|
1,356,364 |
|
Other
assets |
|
|
5,017,632 |
|
|
460,482 |
|
Total
assets |
|
$ |
52,157,696 |
|
$ |
6,766,727 |
|
Liabilities and
Stockholders' Equity |
|
|
|
|
|
|
|
Current liabilities |
|
|
32,368,521 |
|
|
16,520,456 |
|
Long
term liabilities |
|
|
54,639 |
|
|
4,523 |
|
Total
liabilities |
|
|
32,423,160 |
|
|
16,524,979 |
|
Total
stockholders' equity (deficit) |
|
|
19,734,536 |
|
|
(9,758,252 |
) |
Total
Liabilities and Stockholders' Equity |
|
$ |
52,157,696 |
|
$ |
6,766,727 |
|
|
|
|
|
|
|
|
|
Contacts: Matt Sheldon/Evan Pondel PondelWilkinson Inc. (310)
279-5980 Email Contact
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Apr 2023 to Apr 2024